The M&A Pool Set to Accelerate Biotech Innovation
Manage episode 410482806 series 2838531
Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.
45 bölüm